Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M312110200 on December 29, 2003

J. Biol. Chem., Vol. 279, Issue 12, 11553-11561, March 19, 2004
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/12/11553    most recent
M312110200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davoodi-Semiromi, A.
Right arrow Articles by She, J.-X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davoodi-Semiromi, A.
Right arrow Articles by She, J.-X.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

A Mutant Stat5b with Weaker DNA Binding Affinity Defines a Key Defective Pathway in Nonobese Diabetic Mice*

Abdoreza Davoodi-Semiromi{ddagger}§, Malini Laloraya||**, G. Pradeep Kumar||**, Sharad Purohit||, Rajesh Kumar Jha**, and Jin-Xiong She||{ddagger}{ddagger}

From the {ddagger}Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida 32610, ||Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Augusta, Georgia 30912, and **School of Life Sciences, Devi Ahilya University, Vigyan Bhawan, Khandwa Road, Indore (MP) 452001, India

Received for publication, November 5, 2003 , and in revised form, December 22, 2003.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
A number of cytokines that finely regulate immune response have been implicated in the pathogenesis or protection of type 1 diabetes and other autoimmune diseases. It is, therefore, of pivotal importance to examine a family of proteins that serve as signal transducers and activators of transcription (STATs), which regulate the transcription of a variety of cytokines. We report here a defective gene (Stat5b) located on chromosome 11 within a previously mapped T1D susceptibility interval (Idd4) in the nonobese diabetic (NOD) mice. Our sequencing analysis revealed a unique mutation C1462A that results in a leucine to methionine (L327M) in Stat5b of NOD mice. Leu327, the first residue in the DNA binding domain of STAT proteins, is conserved in all identified mammalian STAT proteins. Homology modeling predicted that the mutant Stat5b has a weaker DNA binding, which was confirmed by DNA-protein binding assays. The inapt transcriptional regulation ability of the mutated Stat5b is proved by decreased levels of RNA of Stat5b-regulated genes (IL-2R{beta} and Pim1). Consequently, IL-2R{beta} and Pim1 proteins were shown by Western blotting to have lower levels in NOD compared with normal B6 mice. These proteins have been implicated in immune regulation, apoptosis, activation-induced cell death, and control of autoimmunity. Therefore, the Stat5b pathway is a key molecular defect in NOD mice.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Studies on the NOD mouse model that spontaneously develops T1D have shown that both B and T cells are necessary for the development of the disease (1–4). Other immune cells such as macrophages and dendritic cells have also been implicated in the disease process (5). Despite extensive studies on this animal model, the underlying molecular mechanisms that lead to the development and progression of T1D still remain elusive. The involvement of cytokines that finely regulate immune and hematopoietic systems in the pathogenesis of diabetes has been an area of intense research. A pathogenic role for interferon-{alpha}, interferon-{gamma}, IL-2,1 and IL-l0 has been suggested in T1D development in contrast to a protective role for IL-4, IL-6, and tumor necrosis factor {alpha} (6–9). Since the link between cytokines and T1D is indisputable, it becomes obligatory to examine the cytokine signaling pathways in relation to the disease. Studies of transcriptional activation by interferons and a variety of cytokines have led to the identification of a family of proteins that serve as signal transducers and activators of transcription (STATs). There are seven identified members in this important family of proteins (Statl to Stat4, Stat5a, Stat5b, and Stat6). Upon activation by a large number of cytokines, growth factors, and hormones, STAT proteins are phosphorylated via the Janus kinases, dimerize, translocate to the nucleus, and bind to the promoters of specific target genes (10–13). STAT proteins regulate the expression of a large number of cytokines and their receptors as well as other important molecules involved in immune regulation. In mice, the genes encoding Stat3, Stat5a, and Stat5b map to chromosome 11 (14) within a previously defined Idd4 interval (15). All of the correlative pieces of information led us to explore a plausible connection between T1D and Stat genes on chromosome 11.

This study attempted to use the positional candidate gene approach to test the hypothesis whether functionally chosen candidate genes in the proximity of previously mapped T1D susceptibility intervals are implicated in the disease. We report the identification of a mutation within the DNA binding domain of Stat5b in NOD, which results in diminished DNA binding affinity of Stat5b and reduced expression of downstream genes bearing the Stat5b consensus in their promoter regions.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Animals and Samples
Ten-week-old female mice of six strains including C57B1/6J (B6) and NOD/LtJ (NOD), C3H, NZW, BALB/c, and CBA were obtained from our mouse colony at the University of Florida. Total RNA samples were prepared from spleen cells using standard methods. A subset of mice was induced with 0.5 µg (1 µg/ml) of GM-CSF in PBS with 0.1% bovine serum albumin through intraperitoneal injection. After 20 min of induction, the animals were sacrificed, and tissues were immediately snap-frozen in liquid nitrogen and then stored at -80 °C. Sham-treated controls were injected with 500 µl of 0.1% bovine serum albumin in 0.2-µm filtered PBS (Invitrogen) and sacrificed after 20 min as above. Nuclear and cytoplasmic extracts from spleens were prepared using the method described by Galsgaard et al. (16) with minor modifications. Briefly, tissues were homogenized on ice in hypotonic buffer A (20 mM HEPES, pH 7.9, 10 mM KCl, 1 mM MgCl2, 1 mM EDTA, 1 mM dithiothreitol, 1 mM Na3VO4, 20% glycerol, 1% Triton X-100, 200 µM phenylmethylsulfonyl fluoride, 1 ml/100 ml of phosphatase/inhibitor mixture I, complete Mini protease inhibitor mixture tablet (2 tablets/100 ml). Homogenate was kept for 30 min on ice, and then nuclei were collected by centrifugation at 16,000 rpm at 4 °C for 30 min. Supernatants containing cytosolic protein were transferred to clean tubes and stored at -80 °C for further use. Nuclear protein was extracted from pellets by adding hypertonic buffer B (buffer A with 400 mM NaCl). Each tube was vigorously vortexed for 2 min and then sonicated for 3 s at 18 watts. After centrifugation, 50-µl aliquots of the supernatant (nuclear extract) were made and stored at -80 °C. Protein concentration was measured using the Bio-Rad protein assay.

Sequencing
The entire coding sequence of the Stat5b gene was amplified by PCR in two rounds. The first PCR amplification for Stat5b was carried out with two outside primers: Mstat5b-453F (CACGCGATTCGGGCTCTG) and Mstat5b-2900R (GAAGCGATTCATGGAATTAAAA). The amplified PCR products were then used as templates for nested PCR amplifications. Two overlapping fragments were amplified using two primer pairs: Mstat5b-472F (AGGTGGTGAACCATGGCTAT) and Mstat5b-1746R (CAGACCTCTTGATTCGTTTC) for the 5' fragment and Mstat5b-1591F (AAGGCGACCATCATCAGC) and Mstat5b-2875R (AGGAAGTTCCTCCACGAG) for the 3' fragment. The entire coding region of the Stat3 gene was amplified by reverse transcription-PCR in two rounds. In the first round of PCR amplification, 2 µl of cDNA was used as a template using primers Mstat3-9-F (5'-TGG ACA CAC GCT ACC TGA AG-3') and Mstat3-1261-R (CAG GCT GCC GTT GTT AGA CT). The amplified PCR products were then used for the second round of PCR amplifications using the following primer pair: Mstat3-1020-F (AAG AGT GCC TTC GTG GTG GA) and Mstat3–25l0-R (GCC CAA AGA TAG CAG AAG TAG). The primers used for amplifying Stat5a in the first round are mStat5A-13F (5'-GTC AAG AGC CGT CAG GAG-3') and mStat5A-2556R (GAA ACG TGC AAA GCC ATT GTT). The second round of PCR amplification was done with mStat5A-43F (CCG GCC TGG AGC GAC AAG) and mStat5A-1328R (TTT CTG AAG TGG GCG CTG A) and also mStat5A-1200F (GAA GGC GAC CAT CAT CAG C) and mStat5A-25l2R (GAC GTG GGC TCC TCA CAC TG). The nested PCR products were subjected to direct DNA sequencing using a PerkinElmer 377 automated DNA sequencer.

Electrophoretic Mobility Shift Assays (EMSAs)
Stat5b consensus sequence (5'-TTTCTAGGAATT-3') was used for EMSAs, whereas the mutant oligonucleotide 5'-TTTAGTTTAATT-3' was used as a competitor. Complementary oligonucleotides were used to make double strand DNA, which was end-labeled using 170 µCi of [{gamma}-32P]ATP and T4 polynucleotide kinase. Unincorporated isotope was removed using the QIAquick nucleotide removal kit. Labeled oligonucleotides with a count of ~30,000 cpm were used for EMSA. An equal amount of nuclear protein extract (5 µg) was incubated with double strand oligonucleotides (consensus/mutant) at room temperature for 20 min in a binding buffer (13 mM HEPES, pH 7.9, 80 mM NaCl, 8% glycerol, 0.15 mM EDTA, 1 mM dithiothreitol) (17) and in the presence of poly(dI-dC) (2.5 µg/µl). For competition studies, 10-fold of unlabeled double-stranded oligonucleotide was added in the preincubation step. For supershift assay, the protein extract was first incubated with 0.8 µg of antibody for 20 min at room temperature. Oligonucleotide was then added, and the reaction continued for another 30 min at room temperature. The anti-Stat3 (SC-482X), anti-Stat5a (SC-1081X), anti-Stat5b (SC-835X), and anti-Nmi (sc-9484X) antibodies are rabbit polyclonal antibodies from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). DNA-protein complexes were resolved on a 5% nondenaturing gel containing 5% glycerol and 0.5x TBE. The gels were prerun in 0.5x TBE for 30 min at 150 V. 2 µl of loading mix (40% sucrose, 0.25% bromphenol blue, 0.25% xylene cyanol) was added to each sample before loading. The gels were run at 250 mV for the first 15 min and then at constant 150 mV for about 4 h. The gels were exposed to x-ray films and then kept at -80 °C for at least 48 h.

Microbeads-based Assay for DNA Binding
A new microbeads-based assay was developed with the Luminex system (Luminex Corp.) to study DNA-protein interaction. Briefly, oligonucleotides with a biotin group at the 5'-end were immobilized on Lumavidin 6 microspheres (20 nM/250,000 beads) using a standard conjugation protocol recommended by the manufacturer. The assays were conducted by employing 10,000 oligonucleotide-conjugated beads in a 100-µl reaction containing 13 mM HEPES, 80 mM NaCl, 8% glycerol, 0.15 mM EDTA, 1 mM dithiothreitol, pH 7.9, and 5 µg of protein extracts (or peptide). The reaction was incubated for 1 h at room temperature. The microspheres were pelleted down by centrifugation at 14000 x g for 2 min, washed, and reconstituted in 100 µl of fresh reaction buffer. The reaction was incubated for 1 h with anti-Stat5b antibody (4 µl/100-µl reaction). Once again, the microspheres were pelleted, washed, and resuspended as above. The bound Stat5b antibody was probed with Cy3-labeled anti-rabbit IgG and was detected on a Luminex 100 Flowmetrics system (excitation wavelength 532 nm). The signals originating from the Cy3-labeled secondary antibody reflect the amount of Stat5b protein captured by the oligonucleotides on the beads. We scored 5000 beads for each assay, and the mean fluorescence intensities were computed. The experiment was repeated three times, and the results were averaged. Two peptides were also used in the DNA protein binding assay. These peptides correspond to the DNA binding region (including the mutation L327M) of wild type Stat5b (DIISALVTSTFIIEKQPPQVLK) and mutant (NOD) Stat5b (DIISAMVTSTFIIEKQPPQVLK) and were purchased from New England Peptide, Inc.

SDS-PAGE, Western Blotting, and Immunoblotting
Cytosolic or nuclear proteins were diluted 1:4 with Laemmli sample buffer, and an equal amount of protein (10 µg) from each sample was loaded onto a running gel (pH 8.3) of various concentrations with a 4% stacking gel (pH 6.8). Gels were run on a MiniProtean III vertical electrophoresis system (Bio-Rad) at 100 V for 3 h. The separated proteins were processed for transfer onto Sequiblot polyvinylidene difluoride (0.2 µm; Bio-Rad). For this, the gels were assembled in a transfer module, and the proteins were transferred onto a polyvinylidene difluoride membrane prewet in methanol and equilibrated in transfer buffer (25 mM Tris, 190 mM glycine (pH 8.2), 40% methanol (v/v)) using a Mini Transblot cell (Bio-Rad). The transfer was performed at 15-mA constant current for each membrane for 12–16 h. The blots were developed by the ECL method. For this, the polyvinylidene difluoride membranes were prewet in methanol, washed two times for 5 min into 1x phosphate-buffered saline with 0.1% Tween, followed by blocking (Super Block; Pierce) for 60 min at room temperature with gentle shaking. The membranes were washed five times in PBS-T and incubated for 1 h with optimal concentrations of primary antibodies. After incubation, the membranes were extensively washed five times (5 min each) in PBS-T and then incubated for 60 min with horseradish peroxidase-conjugated secondary antibodies. Visualization was performed using the ECL kit as per the manufacturer's protocol (Amersham Biosciences). Antibodies used in immunoblotting studies were as follows: anti-Stat5b (sc-835), Jak2 (sc-294), Erk-2 (sc-154), IL-2R-{beta} (sc-672), Pim1 (sc-13513), Bag-1 (sc-940), Mcl-1 (sc-958), Bcl-2 (sc-492), and phosphatidylinositol 3-kinase p85{alpha} (sc-423) from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), phosphorylated Stat5b antibody from Upstate Biotechnology (05-495), and Tyk-2 from BIOSOURCE (catalog no. 44-418).

Immunocytochemistry on Spleen Smears
Spleen Smear Preparation—Experimental and sham-treated control subsets were prepared as detailed above. Spleen was excised, detached of adhering fat, washed in Hanks' balanced salt solution (Invitrogen), and ground between two frosted glass plates in 10 ml of Hanks' balanced salt solution buffer and collected in 15-ml sterile tubes. 1 ml of RBC lysis buffer (Sigma) was added, and the cells were shaken gently on a rocker for 1 min. The cells were transferred in a centrifuge tube and sedimented by gravity for 10 min. The supernatant was aspirated and centrifuged for 7 min at 2000 rpm. The pellet was reconstituted in 1 ml of Hanks' balanced salt solution. The cell density was adjusted to 1 x 106 cells/ml. 50 µl of cells were smeared on polylysine-coated slides. The spleen smear slides were fixed in 4% paraformaldehyde by incubation for 30 min. They were air-dried in a hood and store at 4 °C in a slide box.

Immunohistochemistry of Spleen Cells—Immunocytochemistry of spleen smears was done as previously described (18). The fixed spleen smears were washed with PBS-T (0.1% Tween 20) (three washings, 10 min each), neutralized in 50 mM NH4Cl, and permeabilized in 0.25% Triton X-100 followed by blocking in 5% normal goat serum for 2 h. The smears were then incubated with primary antibody, viz. anti-Stat5b rabbit polyclonal (sc-835) from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) (1:200 dilution for 12–18 h). The smears were washed three times for 10 min each and subsequently treated with the relevant secondary antibody, viz. goat anti-rabbit IgG FITC (BG FITC-2) from Bangalore Genei, India (1:200 dilution) for 60 min. The smears were washed three times for 10 min each and processed for nuclear staining by incubating in a 1:1000 dilution of a 1 mg/ml solution of 4',6-diamidino-2-phenylindole-dihydrochloride hydrate for 15 min. The fluorescence was observed using an excitation wavelength of 450–490 nm with a Nikon B-2A filter for FITC conjugates and a 355–375-nm excitation wavelength with a Nikon UV-1A filter for 4',6-diamidino-2-phenylindole. The results were observed under a Nikon epifluorescence microscope, and the images were captured and documented by the COOL SNAP camera and the Documentation System from Alpha Innotech Corp.

Northern Blot
Northern blot was carried out as described previously (19). In brief, 15 µg of total RNA was loaded onto 1.5% agarose gel containing 20% formaldehyde. Electrophoresis was carried out at 150 V for 3 h, and then the gel was blotted to the BrightStar membrane (Ambion) in 20x SSC buffer for overnight. The RNA was cross-linked to the membrane using Crosslinker (Stratagene) according to the manufacturer's instructions. Prehybridization and hybridization were carried out at 42 °C using UltraHyb buffer (Ambion).

3 µg of total RNA was converted to the cDNA by reverse transcriptase and diluted 1:1 by TE buffer. 2 µl of diluted cDNA was used for PCR amplification of the Il-2R{beta} and Pim1 genes. The primers for IL-2R{beta} are a forward primer (5'-GGATGCCGGAAGGTGATG) and a reverse primer (5'-AGGCAGGTACAGGAAGCTA). The primers for PIM1 are a forward primer (5'-GTGAGCTCGGACTTCTCG) and a reverse primer (5'-GATGGTAGCGAATCCACTCT). The PCR products were loaded onto 2% agarose gel, and then the DNA was recovered from the gel using the Qiaquick gel extraction kit (Qiagen). The purified PCR products were labeled with 32P with a random labeling kit (Stratagene), and unincorporated isotope was purified by a SigmaSpin postreaction purification column (Sigma).

Homology Modeling
An initial search for templates for homology modeling of Stat5b was carried out using FASTA-CHECK. The search produced two closely similar templates: 1 BF5 (the crystal structure of Statl) and 1BGF [PDB] (the N terminus of Stat4). A model for the Stat5b-DNA complex was generated by threading the murine Stat5b protein sequence into the crystal coordinates of these two model templates using LOOK II (Molecular Applications Group). The model was energy-minimized using the DISCOVER module of INSIGHT-II (Molecular Simulations Group). The fit was verified by WHAT-IF and PROCHECK 2.0. A mutation of L327M was introduced by the MUTATE function of SWISS-MODEL, and the model was once again energy-minimized. The local field energy around the amino acid at position 327 was mapped before and after the introduction of the mutation.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Sequencing of Stat Genes on Chromosome 11—Three candidate genes within the Idd4 interval on chromosome 11 (Stat3, Stat5a, and Stat5b) were sequenced in NOD and C57BL/6 (B6). Three nucleotide positions in Stat3 and two in Stat5a of both B6 and NOD mice differ from the published sequences (Table I). Since there is no difference between NOD and B6, they are unlikely candidates for diabetes susceptibility factors. Three alterations in Stat5b at positions 433 (G-> A), 767 (G-> C) and 768 (C-> G) are considered as polymorphisms, since they are present in both B6 and NOD animals. Two of the three nucleotide changes are silent mutations. A point mutation (C1462A) in the NOD leads to a substitution of leucine to methionine at position 327 (L327M), the first amino acid of the DNA binding domain of the STAT proteins (Fig. 1, A and B). This mutation was not found in the five control strains (B6, C3H, NZW, BALB/c, and CBA). The Leu327 residue is conserved in all STAT proteins sequenced to date.


View this table:
[in this window]
[in a new window]
  		TABLE I
Mutations found in the Stat3, Stat5a, and Stat5b genes Mutations are shown in boldface type.

 



View larger version (55K):
[in this window]
[in a new window]
  		FIG. 1.
Mutation in the DNA binding domain of Stat5b of NOD mice. A, DNA sequence electropherograms indicating the mutated genotype. B, amino acid sequence alignment of the DNA binding domains of the STAT family of proteins. Leu327, the first amino acid within the DNA binding domain, is conserved in all STAT proteins that have been sequenced to date. Leu327 is also conserved in Stat5b from C57BL6, C3H, NZW, BALB/c, and CBA strains of mice, as determined by this study. The DNA sequence of Stat5b from NOD mice revealed a single point mutation C1462A, which leads to the substitution of leucine by methionine at position 327. This change is unique to the NOD mice. C and D, molecular modeling of Stat5b. Crystal structures of Statl (Protein Data Bank entry lBF5) and Stat 4 (Protein Data Bank entry lBGF) were used as templates for creating the Stat5b model. The murine Stat5b sequence was threaded into the crystal coordinates of these templates to generate the predicted structure of the full-length murine Stat5b. The magnified view of the Stat5b DNA binding region depicts the interaction between Stat5b and the DNA-binding sequence. C, model for the wild type Stat5b protein from B6 and other strains. The consensus DNA binding motif (TTNNNNNAA) is drawn in a space fill model, where TT is shown in orange, N5 in blue, and AA in red. Leu327, drawn in a yellow space fill, shows interdigitation with TT of the consensus DNA motif. D, model for the mutant Stat5b protein from NOD. This view depicts the effect of substitution of leucine with methionine (Leu327 -> Met327). Methionine is drawn in a green space fill, and this change introduces physical distance between DNA and protein at this interacting plane as a consequence of the increased side chain volume and bulk hydrophobicity. Local stearic hindrance caused by this mutation is predicted to result in weakened DNA-protein interactions.

 
The potential impact of the L327M mutation on the DNA binding ability of Stat5b was assessed by homology modeling for the wild type and mutant Stat5b. As shown in Fig. 1C, leucine 327 (yellow residue) of the wild type Stat5b establishes contacts with the palindromic DNA binding sequence (TTCN3GAA) at the TT positions. The replacement of leucine with methionine (green residue in Fig. 1D) increases the side chain volume and the bulk hydrophobicity around the critical contact point. The local energy values drift from +185 kJ/mol to -33 kJ/mol when methionine replaces leucine. This change would abolish the side chain interdigitation between Leu327 and the thymidine. This introduces a spatial barrier between the Met327 side chain and the thymidine residue (Fig. 1D), which would reduce the ability of methionine to interact with the DNA sequence. Therefore, the mutant Stat5b is predicted to exhibit a weaker DNA binding affinity.

DNA Binding Affinity of Stat5b—The DNA binding ability was compared between the wild type (B6) and mutant (NOD) Stat5b using an EMSA. Protein extracts from the cytosolic and nuclear fractions were prepared from splenocytes with and without in vivo stimulation with GM-CSF. Western blot with anti-Stat5b antibody showed that the levels of cytosolic fraction, phosphorylated cytosolic fraction, and nuclear Stat5b are comparable in NOD and B6 (Fig. 2A). These results are complemented with immunocytochemical analysis showing similar cytosolic and nuclear Stat5b levels in spleen cells from B6 and NOD mice (Fig. 2B). Consistently, similar levels of proteins were found in NOD and B6 for the upstream mediators for the activation of Stat5b including the Jak2, tyrosine kinase 2 (Tyk2), and extracellular signal-regulated kinases (Erkl and Erk2) involved in phosphorylation of STATs (Fig. 2C).



View larger version (21K):
[in this window]
[in a new window]
  		FIG. 2.
Expression levels of key proteins in the Janus kinase-STAT pathway. Six individual mice for each strain were analyzed for each protein, and only two representative samples are shown here. A, Western blots showing levels of cytoplasmic Stat5b, phosphorylated fraction of cytoplasmic Stat5b, and nuclear Stat5b in the spleen of B6 and NOD mice without GM-CSF induction and 20 min after GM-CSF induction. B, immunocytochemical localization of Stat5b with parallel 4',6-diamidino-2-phenylindole-dihydrochloride hydrate (DAPI) nuclear staining in B6 and NOD spleen cells from sham-injected animals and GM-CSF-injected animals. C, protein levels of Jak2, Tyk2, and Erkl/2 kinases in cytosolic extracts from B6 and NOD spleens without GM-CSF induction and 20 min after GM-CSF induction.

 
Nuclear extracts were used in EMSA with the consensus DNA sequence recognized by Stat5 proteins (20). Both B6 and NOD animals showed strong gel shift with the Stat5 consensus sequence in the samples stimulated with GM-CSF as compared with a negligible shift in the unstimulated preparations (Fig. 3A). A supershift assay using polyclonal anti-Stat5b antibody showed that the Stat5b-specific DNA-protein complexes are about 5-fold higher in B6 than NOD mice (Fig. 3A, lane 5 versus lane 9). It is important to note that NOD nuclear extracts bound the Stat consensus represented by the shift position in Fig. 3A, lane 8. The Stat5b-specific DNA binding is attributable only to the supershifted band. An explanation for the weaker supershifted band could simply be that the antibody does not recognize the NOD form of Stat5b with the same affinity as the B6 form. This does not appear to hold any validity, since in all Western blots the same antibody recognized Stat5b in cytosolic and nuclear extracts with the same affinity, and no differences in the quantities of Stat5b were detectable (Fig. 2A), thus indicating that antigen-antibody binding is not affected by the mutation. Our immunofluorescence data in spleen cells for Stat5b levels show similar quantities in the cytosol and in the nucleus in both B6 and NOD. Once again, this suggests that the antigen-antibody binding is more or less unaffected by the mutation. Additionally, our combined Western and immunofluorescence data suggest similar nuclear export of the protein in both of these models. The antibody sc-835 (Santa Cruz Biotechnology) has been extensively used by others in analyzing Stat5b-specific supershifts (21, 22).



View larger version (77K):
[in this window]
[in a new window]
  		FIG. 3.
DNA binding of Stat5b from B6 and NOD mice assayed using EMSA. A, nuclear extracts from spleens of B6 and NOD mice were incubated with Stat5b-binding consensus sequence TTCN3GAA. Before stimulation with GM-CSF, both B6 and NOD mice showed very weak gel shift (lanes 2 and 6), and Stat5b-specific supershifts were also undetectable (lanes 3 and 7). Stimulation with GM-CSF brought about the appearance of gel-shifted bands in both B6 and NOD animal (lanes 4 and 8). Stat5b-specific supershifts were much stronger in B6 (lane 5) than NOD (lane 9) mice. The Stat5b simple and supershift assays were carried out in six animals from each strain, and the experiment was repeated three times. The histogram on the right represents the mean and S.E. of normalized band intensities of the Stat5b-specific supershifts in B6 and NOD mice. The Stat5b-specific supershifts were 5-fold higher in B6 animals than NOD, and the difference was statistically highly significant (p < 10-5). Lane 1, free label. B, EMSA showing specificity of Stat5b binding. Use of a 10-fold excess of the cold consensus oligonucleotide brought about a total reduction of the gel-shifted band in both B6 (lane 3) and NOD (lane 6) nuclear extracts. A mutant oligonucleotide in gel shift assays did not show shift for B6 (lane 4) or NOD (lane 7). C, antibodies to Stat5a did not bring about supershifts of the shifted bands in B6 (lane 2) or NOD (lane 4). Similarly, anti-Stat3 also failed to introduce supershifts of the shifted complexes in B6 (lane 6) and NOD (lane 8) animals. Nmi, an interacting partner of Stat5b, also did not bring about a supershift in B6 (lane 10) and NOD (lane 12) animals. Lane 1, free label.

 
The specificity of the gel shift assay was confirmed using competition with mutated DNA and cold consensus oligonucleotide. The addition of a 10-fold molar excess of cold consensus oligonucleotide caused a complete disruption of the Stat5-DNA complex in extracts from both B6 and NOD mice, signifying the specificity of the interaction (Fig. 3B, lanes 3 and 6). Further, the use of a hot mutant Stat5b consensus with base replacements at underlined positions 5'-TTA GTT TAA-3' also showed the inability of the mutant oligonucleotide to bind to the Stat5b protein from B6 and NOD nuclear extracts (Fig. 3B, lanes 4 and 7), confirming the specificity of the binding.

Supershift assays with antibodies against Stat5a and Stat3, which may be associated with Stat5b (23), indicated that the Stat5b complexes do not contain Stat5a (Fig. 3C, lanes 2 and 4) or Stat3 (Fig. 3C, lanes 6 and 8). Together, these results indicate that the weaker Stat5b-specific supershifted complexes in NOD mice were attributable to the impaired DNA binding of the mutant protein. These data are consistent with previous observations that mutations within the DNA-binding region result in Stat proteins that are activated normally but have greatly reduced DNA binding (24–27).

The coexistence of other proteins along with Stat5b-DNA complex has been reported. N-Myc interactor (Nmi) is identified as a Stat-interacting partner using a yeast two-hybrid assay. It also enhances the association of CREB-binding protein/p300 coactivator proteins with Stat1 and Stat5 and, together with CREB-binding protein/p300, augments IL-2 and interferon {gamma}-dependent transcription. Thus, Nmi potentiates STAT-dependent transcription and can also augment coactivator protein recruitment to at least some members of a group of sequence-specific transcription factors (28). In order to understand the nature of the nonsupershifted band, we checked whether it can be supershifted using Nmi. The lack of coexistence of Nmi in the protein-DNA complex is also evident from the inability of anti-Nmi to supershift the shifted complex (Fig. 3C, lanes 10 and 12). Thus, we excluded the presence of Stat5a, Stat3, and Nmi in the protein-DNA complex. Centrosomal P4.1-associated protein has recently been shown to specifically interact with Stat5a and Stat5b but not with Stat1 or Stat3 using yeast two-hybrid screen of HBL100 and primary breast adenocarcinoma libraries and is thought to cotranslocate to the nucleus along with activated STAT and augment STAT-mediated transcription (29). We are currently trying to understand the nature of this nonsupershifted band and suspect the involvement of novel yet unidentified Stat5b-interacting partners.

Microbeads-based Assay for DNA Binding—Another possibility for the observed weaker supershift for Stat5b of NOD could be argued as a result of a yet unidentified NOD-specific competitor protein that could change the binding of the Stat5b antibody. To test this unlikely possibility, we evaluated the binding affinity of wild type versus mutant peptides corresponding to the Stat5b binding domain. For this purpose, we have developed a new assay for DNA-binding studies using the microbeads-based technology from Luminex. The strategy in this assay is to immobilize the oligonucleotides with 5'-biotin on the surface avidin of the proprietary microbeads. A double-discriminate analysis of the emission coming from the mobile phase (bead in buffer) would help detect the physical presence of a bead in the light path. The addition of a ligand under test and the detection of the ligand with a fluorophore-conjugated antibody to the ligand would yield a second emission line. The presence of two emission lines (one coming from the bead and the other one coming from the antibody) would permit the demonstration of the binding of the ligand to the microbead through the test ligand-binding entity. We initially applied the assay to the Stat5b wild type and mutant peptides corresponding to the DNA binding domain of the Stat5b protein. The assay developed exhibited typical concentration-dependent kinetics (Fig. 4C). As shown in Fig. 4A (bars 1 and 2), the wild type and mutant Stat5b peptides can bind with Stat5b-consensus oligonucleotide compared with a control oligonucleotide (ATTGGTTA) (bars 3 and 4). These data suggest that the binding is specific to the Stat5b binding sequence. The inset represents a dot blot of wild type (B6) and mutant (NOD) Stat5b peptide reactivity with Stat5b (sc-835) antibody. None of the controls, comprising Stat5b consensus oligonucleotide plus Cy-labeled secondary antibody (bar 5), Stat5b consensus oligonucleotide plus control antibody (anti-Aire antibody) and Cy-labeled secondary antibody (bar 6), and Stat5b consensus oligonucleotide plus B6 peptide and Cy-labeled secondary antibody (bar 7), showed any detectable binding. The studies also indicated that the binding of the wild type peptide to the Stat5b consensus sequence is ~3.6 times stronger than that of the mutant (NOD) peptide (p < 5.7 x l0-7). This is consistent with the results from EMSA. We also applied the same assay to nuclear protein extracts from NOD and B6 spleens (Fig. 4B). Again, wild type (B6) showed 4 times stronger binding to the Stat5b consensus sequence than mutant (NOD) Stat5b (p < 0.005). Control oligonucleotide did not bind Stat5b (data not shown), showing the specificity of the interactions in the assays.



View larger version (35K):
[in this window]
[in a new window]
  		FIG. 4.
Microbeads-based assay for DNA-binding affinity. A, Flowmetrics assays of the binding of Stat5b peptides with Stat5b-consensus oligonucleotide. Bars 1 and 2, the binding efficiencies of wild type Stat5b peptide and mutant (NOD) Stat5b peptide with Stat5b consensus oligonucleotide. Bars 3 and 4, the binding of normal and mutant Stat5b peptide with a nonconsensus oligonucleotide (ATTGGTTA). None of the controls comprising Stat5b consensus oligonucleotide plus Cy-labeled secondary antibody (bar 5), Stat5b consensus oligonucleotide plus Aire antibody and Cy3-labeled secondary antibody (bar 6), and Stat5b consensus oligonucleotide plus B6 peptide and Cy-labeled secondary antibody (bar 7) showed any detectable binding. The inset represents recognition of the B6 and NOD peptide by Stat5b antibody in dot blot assays. B, binding efficiencies of Stat5b in B6 and NOD nuclear protein extracts from the spleen to Stat5b consensus oligonucleotide. Nonconsensus oligonucleotide did not bind Stat5b (bars not presented), showing the specificity of the interactions in our assays. C, kinetics of microfluidics assay of the binding of STAT peptides to STAT consensus (5'-TTTCTAGGAATT-3') and mutant (5'-TTTAGTTTAATT-3') oligonucleotides immobilized on the Lumavidin microbead assay using biotin-avidin immobilization chemistry. Immobilized mutant oligonucleotide with wild type STAT peptide ({blacktriangleup}) or the mutant peptide (x) showed very weak signal and served as control for the background. Immobilized STAT consensus oligonucleotide bound wild type Stat peptide in a concentration-dependent fashion ({diamondsuit}), whereas the binding of the STAT consensus with (NOD) mutant STAT peptide ({blacksquare}) was significantly weaker.

 
Expression of Genes Regulated by Stat5b—We examined the impact of the Stat5b mutation on the expression levels of downstream genes directly regulated by Stat5b. Two of the genes with potential Stat5b binding sites in their promoter (Il-2R{beta} and Pim1) were analyzed as candidate downstream Stat5b effectors. Northern analysis was performed in order to probe alteration in RNA levels to prove the differential transcriptional regulation of normal versus mutated Stat5b. Il-2R{beta} mRNA was induced strongly in B6 mice by GM-CSF at both 20-min (p < 0.05) and 2-h (p < 0.02) induction time when compared with NOD mice (Fig. 5A). After 20 min of GM-CSF induction, Pim1 mRNA is induced more strongly in B6 mice compared with NOD mice (p < 0.02) (Fig. 5A). Interestingly, at 2-h induction, the GM-CSF-mediated signal transduction died off for the Pim1 gene, suggesting an early gene regulation.



View larger version (32K):
[in this window]
[in a new window]
  		FIG. 5.
Differential regulation of Stat5b target genes in B6 and NOD mice under the influence of GM-CSF. A, Northern blot. Expression levels are shown for IL-2R{beta} and Pim1 without GM-CSF induction and 20 min or 2 h after GM-CSF induction in vivo. B, Western blot for IL-2R{beta} and Pim1 in cytosolic extracts from B6 and NOD spleens without GM-CSF induction and 20 min after GM-CSF induction. Six animals in each strain were analyzed. The mean and S.D. of the signal intensity for each group are presented by the bars on the right, which represent protein levels in GM-CSF-induced B6 and NOD spleen extracts. Student's t tests were performed to show statistical significance between B6 (gray bars) and NOD (white bars) mice: IL-2R{beta} (p < 5 x 10-6) and Pim1 (p < 0.001). C, Western blot analysis showing comparable protein levels of four Stat3-regulated genes in B6 and NOD spleens without GM-CSF induction and 20 min after GM-CSF induction.

 
Il-2R{beta} and perforin are shown to have weaker protein expression in splenocytes of Stat5b-/-mice (26). Our immunoblotting assays show weaker protein expression of Il-2R{beta} (p < 5.5 x l0-6) and Pim1 (p < 0.001) in NOD splenic extracts compared with B6 splenic extracts (Fig. 5B). These results are consistent with the weaker DNA binding of the mutant Stat5b in NOD followed by lower mRNA levels. Western blot analysis was also performed for Stat3-regulated genes. Cytosolic extracts from the spleen of B6 and NOD mice were probed with antibodies to Bag-1, Mcl-1, Bcl-2, and phosphatidylinositol 3-kinase p85{alpha}. The levels of these proteins were similar in NOD and B6 mice, indicating that the Stat3-dependent pathways are not impaired in the NOD (Fig. 5C).


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
Our sequencing studies revealed a unique mutation (C1462A) in Stat5b of NOD. The mutation is within the DNA binding domain of the Stat5b protein, and the residue is a conserved amino acid in all the seven members of the STAT gene family as well as in various animal species including mice, rats, sheep, bovines, and humans (Fig. 1). Computer modeling has shown that this substitution of leucine to methionine (L327M) may decrease the binding affinity of the Stat5b protein to DNA. Consequently, we performed a number of studies to experimentally demonstrate the defective function associated with this mutation. Using classical EMSA supershift assay, we showed that the Stat5b protein from NOD has a weaker DNA binding affinity to Stat5b consensus sequence. We have confirmed the weaker binding of NOD Stat5b using a newly developed microbeads-based DNA/protein interaction assay. This finding is further supported by DNA/protein interaction assay with wild type and mutant (NOD) peptides. Therefore, the collection of evidence strongly supports our conclusion that the mutant Stat5b from NOD has a decreased binding to Stat5b consensus sequence.

The differential transcriptional regulation ability of normal and mutated Stat5b is proved by alterations in RNA levels of downstream genes bearing the Stat5b binding motif in their promoter. GM-CSF caused a marked induction of Il-2R{beta} and Pim1 mRNA expression in B6 mice, who carry the wild type Stat5b gene. In contrast, GM-CSF induced very weak IL-2R{beta} and Pim1 mRNA expression in NOD animals that carry the mutated Stat5b gene. The reduced DNA binding of NOD Stat5b manifested in the form of decreased expression of Stat5b-regulated genes as well as their protein products. These proteins are likely to be implicated in the pathogenesis of T1D. IL-2 is a cytokine produced by activated T cells and regulates T cell immune response following antigen encounter. The activation of Stat5 is one of the earliest signaling events mediated by IL-2 family cytokines (30). Mice lacking IL-2, the {alpha} or {beta} chain of IL-2R develop lymph adenopathy and various manifestations of autoimmunity (31). IL-2 and IL-2R knockout mice manifest severe immune system abnormalities characterized by a lymphoadenopathy, splenomegaly, uncontrolled activation and proliferation of lymphocytes, and T cell infiltration of the bone marrow (32), indicating that IL-2 is a nonredundant determinant of T cell tolerance and autoimmunity. The IL-2 gene is also localized within a type 1 diabetes interval, and a functional polymorphism was observed for the IL-2 molecule in NOD mice (33, 34). Therefore, the decreased level of IL-2R{beta} in NOD may contribute to the development of autoimmunity similar to the occurrence in IL-2R-/- mice.

Many oncogenes such as Myc are capable of inducing both cell proliferation and apoptosis (35–38). Pim1 is a serine/threonine kinase, and the protein cooperates specifically with c-Myc in lymphogenesis. Pim1 stimulates c-Myc-mediated apoptosis upstream of caspase-3-like protease. Overexpression of Pim1 can also overcome some of the proliferative defects caused by defective interleukin signaling, supporting a role of Pim1 in cell proliferation (39). Since Myc-induced apoptosis occurs in cells with high Myc protein, the diminished Pim1 expression would lead to a defective c-Myc expression, which may account for lowered apoptosis of cytotoxic T lymphocytes, thus providing them an escape mechanism leading to accumulation of autore-active T cells in NOD. Indeed, lymphocytes of NOD mice are resistant to several apoptotic stimuli (40, 41). Activated T lymphocytes from NOD showed a markedly increased resistance to induction of apoptosis following deprivation of IL-2 (42). Overexpression of c-Myc counteracts diabetic alterations in transgenic mice through its ability to induce hepatic glucose uptake and utilization and to block the activation of gluconeogenesis and ketogenesis (43).

Leptin and its receptor, obese receptor (OB-R) comprise an important signaling system for regulation of body weight. A point mutation within the OB-R gene of diabetic mice is known to generate a new splice donor, which reduces expression of long form. A short isoform of OB-R is unable to activate the STAT pathway, whereas the long isoforms of OB-R activates Stat3, Stat5, and Stat6 (44). These works contribute to establish the importance of the STAT pathway in diabetes. Our results showing no difference in the Stat5b levels in the cytosol or the nucleus of B6 and NOD levels indicate that the mutation does not effect the nuclear transport of Stat5b in both the models; nor is the sequel of events involved in phosphorylation of Stat5b defective in B6 and NOD mice.

In summary, a mutant Stat5b with weak DNA binding in NOD may exert multiple effects on the development of T1D. The diminished expressions of IL-2R{beta}, and Pim1 in NOD may explain some of the key malfunctions associated with the disease, including defects in cytokine signaling, T cell selection, and lymphoid cell apoptosis. Furthermore, Stat5b also regulates the expression of many other genes including insulin (16), Irf-l (45), CIS2 (46), {beta}-casein (47), intercellular adhesion molecule-1 (45), Bcl-X (47, 48), and insulin-like growth factor. Many of these genes may play critical roles in the pathogenesis of T1D. The discovery of a defective Stat5b pathway provides new avenues to the studies of the pathogenesis of T1D, and attempts to rescue the DNA binding ability of mutated Stat5b would be of immense therapeutic importance.


   FOOTNOTES
 
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AYO4O231 (Stat5b of NOD) and AYO429O6 (Stat5b of B6).

* This work was supported in part by National Institutes of Health Grant POI AI-42288 (to J.-X. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

§ Supported by postdoctoral fellowships from the Juvenile Diabetes Research Foundation (JDF3-1999-671 and JDFl0-200l-589). Back

These authors contributed equally to this work. Back

{ddagger}{ddagger} To whom correspondence should be addressed: Center for Biotech nology and Genomic Medicine, Medical College of Georgia, 1120 15th St., PV6B108, Augusta, GA 30912. Tel.: 706-823-3973; Fax: 706-823-2269; E-mail: jshe{at}mail.mcg.edu.

1 The abbreviations used are: IL, interleukin; STAT, signal transducers and activators of transcription; GM-CSF, granulocyte-macrophage colony-stimulating factor; PBS, phosphate-buffered saline; EMSA, electrophoretic mobility shift assay; NOD, nonobese diabetic; FITC, fluorescein isothiocyanate; CREB, cAMP-response-binding protein; OB-R, obese receptor. Back


   ACKNOWLEDGMENTS
 
We thank Dr. Andrew Muir for insightful comments on the manuscript.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Akashi, T., Nagafuchi, S., Anzai, K., Kondo, S., Kitamura, D., Wakana, S., Ono, J., Kikuchi, M., Niho, Y., and Watanabe, T. (1997) Int. Immunol. 9, 1159-1164[Abstract/Free Full Text]
  2. Christianson, S. W., Shultz, L. D., and Leiter, E. H. (1993) Diabetes 42, 44-55[Abstract]
  3. Noorchashm, H., Noorchashm, N., Kern, J., Rostami, S. Y., Barker, C. F., and Naji, A. (1997) Diabetes 46, 941-946[Abstract]
  4. Serreze, D. V., Chapman, H. D., Varnum, D. S., Hanson, M. S., Reifsnyder, P. C., Richard, S. D., Fleming, S. A., Leiter, E. H., and Shultz, L. D. (1996) J. Exp. Med. 184, 2049-2053[Abstract/Free Full Text]
  5. Yoon, J. W., and Jun, H. S. (2001) Ann. N. Y. Acad. Sci. 928, 200-211[Medline] [Order article via Infotrieve]
  6. Goudy, K., Song, S., Wasserfall, C., Zhang, Y. C., Kapturczak, M., Muir, A., Powers, M., Scott-Jorgensen, M., Campbell-Thompson, M., Crawford, J. M., Ellis, T. M., Flotte, T. R., and Atkinson, M. A. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 13913-13918[Abstract/Free Full Text]
  7. Rabinovitch, A., and Suarez-Pinzon, W. L. (1998) Biochem. Pharmacol. 55, 1139-1149[CrossRef][Medline] [Order article via Infotrieve]
  8. Rabinovitch, A. (1998) Diabetes Metab. Rev. 14, 129-151[CrossRef][Medline] [Order article via Infotrieve]
  9. Zhang, Y. C., Pileggi, A., Agarwal, A., Molano, R. D., Powers, M., Brusko, T., Wasserfall, C., Goudy, K., Zahr, E., Poggioli, R., Scott-Jorgensen, M., Campbell-Thompson, M., Crawford, J. M., Nick, H., Flotte, T., Ellis, T. M., Ricordi, C., Inverardi, L., and Atkinson, M. A. (2003) Diabetes 52, 708-716[Abstract/Free Full Text]
  10. Chatterjee-Kishore, M., van den, A. F., and Stark, G. R. (2000) Trends Cell Biol. 10, 106-111[CrossRef][Medline] [Order article via Infotrieve]
  11. Hoey, T., and Schindler, U. (1998) Curr. Opin. Genet. Dev. 8, 582-587[CrossRef][Medline] [Order article via Infotrieve]
  12. Horvath, C. M. (2000) Trends Biochem. Sci. 25, 496-502[CrossRef][Medline] [Order article via Infotrieve]
  13. Imada, K., and Leonard, W. J. (2000) Mol. Immunol. 37, 1-11[CrossRef][Medline] [Order article via Infotrieve]
  14. Copeland, N. G., Gilbert, D. J., Schindler, C., Zhong, Z., Wen, Z., Darnell, J. E., Jr., Mui, A. L., Miyajima, A., Quelle, F. W., Ihle, J. N., and Jenkins, N. A. (1995) Genomics 29, 225-228[CrossRef][Medline] [Order article via Infotrieve]
  15. McDuffie, M. (2000) Clin. Immunol. 96, 119-130[CrossRef][Medline] [Order article via Infotrieve]
  16. Galsgaard, E. D., Gouilleux, F., Groner, B., Serup, P., Nielsen, J. H., and Billestrup, N. (1996) Mol. Endocrinol. 10, 652-660[Abstract/Free Full Text]
  17. Storz, P., Doppler, H., Pfizenmaier, K., and Muller, G. (1999) FEBS Lett. 464, 159-163[CrossRef][Medline] [Order article via Infotrieve]
  18. Saxena, D., Purohit, S. B., Kumer, G. P., and Laloraya, M. (2000) Nitric Oxide 4, 384-391[CrossRef][Medline] [Order article via Infotrieve]
  19. Wilson, K. H., Eckenrode, S. E., Li, Q. Z., Ruan, Q. G., Yang, P., Shi, J. D., Davoodi-Semiromi, A., McIndoe, R. A., Croker, B. P., and She, J. X. (2003) Diabetes 52, 2151-2159[Abstract/Free Full Text]
  20. Gouilleux, F., Pallard, C., Dusanter-Fourt, I., Wakao, H., Haldosen, L. A., Norstedt, G., Levy, D., and Groner, B. (1995) EMBO J. 14, 2005-2013[Medline] [Order article via Infotrieve]
  21. Zhou, Y. C., and Waxman, D. J. (1999) J. Biol. Chem. 274, 29874-29882[Abstract/Free Full Text]
  22. Zhou, Y. C., and Waxman, D. J. (1999) J. Biol. Chem. 274, 2672-2681[Abstract/Free Full Text]
  23. Al Shami, A., Mahanna, W., and Naccache, P. H. (1998) J. Biol. Chem. 273, 1058-1063[Abstract/Free Full Text]
  24. Boucheron, C., Dumon, S., Santos, S. C., Moriggl, R., Hennighausen, L., Gisselbrecht, S., and Gouilleux, F. (1998) J. Biol. Chem. 273, 33936-33941[Abstract/Free Full Text]
  25. Horvath, C. M., Wen, Z., and Darnell, J. E., Jr. (1995) Genes Dev. 9, 984-994[Abstract/Free Full Text]
  26. Imada, K., Bloom, E. T., Nakajima, H., Horvath-Arcidiacono, J. A., Udy, G. B., Davey, H. W., and Leonard, W. J. (1998) J. Exp. Med. 188, 2067-2074[Abstract/Free Full Text]
  27. Schindler, U., Wu, P., Rothe, M., Brasseur, M., and McKnight, S. L. (1995) Immunity 2, 689-697[CrossRef][Medline] [Order article via Infotrieve]
  28. Zhu, M., John, S., Berg, M., and Leonard, W. J. (1999) Cell 96, 121-130[CrossRef][Medline] [Order article via Infotrieve]
  29. Peng, B., Sutherland, K. D., Sum, E. Y., Olayioye, M., Wittlin, S., Tang, T. K., Lindeman, G. J., and Visvader, J. E. (2002) Mol. Endocrinol. 16, 2019-2033[Abstract/Free Full Text]
  30. Lin, J. X., and Leonard, W. J. (2000) Oncogene 19, 2566-2576[CrossRef][Medline] [Order article via Infotrieve]
  31. Sadlack, B., Merz, H., Schorle, H., Schimpl, A., Feller, A. C., and Horak, I. (1993) Cell 75, 253-261[CrossRef][Medline] [Order article via Infotrieve]
  32. Klebb, G., Autenrieth, I. B., Haber, H., Gillert, E., Sadlack, B., Smith, K. A., and Horak, I. (1996) Clin. Immunol. Immunopathol. 81, 282-286[CrossRef][Medline] [Order article via Infotrieve]
  33. Denny, P., Lord, C. J., Hill, N. J., Goy, J. V., Levy, E. R., Podolin, P. L., Peterson, L. B., Wicker, L. S., Todd, J. A., and Lyons, P. A. (1997) Diabetes 46, 695-700[Abstract]
  34. Podolin, P. L., Wilusz, M. B., Cubbon, R. M., Pajvani, U., Lord, C. J., Todd, J. A., Peterson, L. B., Wicker, L. S., and Lyons, P. A. (2000) Cytokine 12, 477-482[CrossRef][Medline] [Order article via Infotrieve]
  35. Desbarats, L., Schneider, A., Muller, D., Burgin, A., and Eilers, M. (1996) Experientia 52, 1123-1129[CrossRef][Medline] [Order article via Infotrieve]
  36. Eilers, M. (1999) Mol. Cells 9, 1-6[Medline] [Order article via Infotrieve]
  37. Evan, G., and Littlewood, T. (1998) Science 281, 1317-1322[Abstract/Free Full Text]
  38. Prendergast, G. C. (1999) Oncogene 18, 2967-2987[CrossRef][Medline] [Order article via Infotrieve]
  39. Berns, A., Mikkers, H., Krimpenfort, P., Allen, J., Scheijen, B., and Jonkers, J. (1999) Cancer Res. 59, (suppl.) 1773-1777
  40. Colucci, F., Cilio, C. M., Lejon, K., Goncalves, C. P., Bergman, M. L., and Holmberg, D. (1996) J. Autoimmun. 9, 271-276[CrossRef][Medline] [Order article via Infotrieve]
  41. Colucci, F., Bergman, M. L., Penha-Goncalves, C., Cilio, C. M., and Holmberg, D. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 8670-8674[Abstract/Free Full Text]
  42. Garchon, H. J., Luan, J. J., Eloy, L., Bedossa, P., and Bach, J. F. (1994) Eur. J. Immunol. 24, 380-384[Medline] [Order article via Infotrieve]
  43. Riu, E., Bosch, F., and Valera, A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2198-2202[Abstract/Free Full Text]
  44. Ghilardi, N., and Skoda, R. C. (1997) Mol. Endocrinol. 11, 393-399[Abstract/Free Full Text]
  45. Schindler, C., and Darnell, J. E., Jr. (1995) Annu. Rev. Biochem. 64, 621-651[Medline] [Order article via Infotrieve]
  46. Yoshimura, A., Ohkubo, T., Kiguchi, T., Jenkins, N. A., Gilbert, D. J., Copel- and, N. G., Hara, T., and Miyajima, A. (1995) EMBO J. 14, 2816-2826[Medline] [Order article via Infotrieve]
  47. Silva, M., Benito, A., Sanz, C., Prosper, F., Ekhterae, D., Nunez, G., and Fernandez-Luna, J. L. (1999) J. Biol. Chem. 274, 22165-22169[Abstract/Free Full Text]
  48. Socolovsky, M., Fallon, A. E., Wang, S., Brugnara, C., and Lodish, H. F. (1999) Cell 98, 181-191[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
Y. D. Dai, I. G. Marrero, P. Gros, H. Zaghouani, L. S. Wicker, and E. E. Sercarz
Slc11a1 Enhances the Autoimmune Diabetogenic T-Cell Response by Altering Processing and Presentation of Pancreatic Islet Antigens
Diabetes, January 1, 2009; 58(1): 156 - 164.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. McDuffie, N. A. Maybee, S. R. Keller, B. K. Stevens, J. C. Garmey, M. A. Morris, E. Kropf, C. Rival, K. Ma, J. D. Carter, et al.
Nonobese Diabetic (NOD) Mice Congenic for a Targeted Deletion of 12/15-Lipoxygenase Are Protected From Autoimmune Diabetes
Diabetes, January 1, 2008; 57(1): 199 - 208.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Enzler, S. Gillessen, M. Dougan, J. P. Allison, D. Neuberg, D. A. Oble, M. Mihm, and G. Dranoff
Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of {beta} cells
Blood, August 1, 2007; 110(3): 954 - 961.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. Brusko, C. Wasserfall, K. McGrail, R. Schatz, H. L. Viener, D. Schatz, M. Haller, J. Rockell, P. Gottlieb, M. Clare-Salzler, et al.
No Alterations in the Frequency of FOXP3+ Regulatory T-Cells in Type 1 Diabetes
Diabetes, March 1, 2007; 56(3): 604 - 612.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Laloraya, A. Davoodi-Semiromi, G. P. Kumar, M. McDuffie, and J.-X. She
Impaired Crkl Expression Contributes to the Defective DNA Binding of Stat5b in Nonobese Diabetic Mice
Diabetes, March 1, 2006; 55(3): 734 - 741.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. A. Litherland, K. M. Grebe, N. S. Belkin, E. Paek, J. Elf, M. Atkinson, L. Morel, M. J. Clare-Salzler, and M. McDuffie
Nonobese Diabetic Mouse Congenic Analysis Reveals Chromosome 11 Locus Contributing to Diabetes Susceptibility, Macrophage STAT5 Dysfunction, and Granulocyte-Macrophage Colony-Stimulating Factor Overproduction
J. Immunol., October 1, 2005; 175(7): 4561 - 4565.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Kotani, I.-m. Okazaki, M. Muramatsu, K. Kinoshita, N. A. Begum, T. Nakajima, H. Saito, and T. Honjo
A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression
PNAS, March 22, 2005; 102(12): 4506 - 4511.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/12/11553    most recent
M312110200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davoodi-Semiromi, A.
Right arrow Articles by She, J.-X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davoodi-Semiromi, A.
Right arrow Articles by She, J.-X.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement